Clinical Efficacy and Safety of Buyang Huanwu Decoction for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials

Table 5

Meta-analyses of the scores of neurological deficit of BHD therapy for acute ischemic stroke.

Study or subgroup	Experimental			Control			Weight	Mean difference	Mean difference
	Events	SD	Total	Events	SD	Total		IV, random, 95% CI	IV, random, 95% CI
Chen, 2007 [32]	13.55	9.22	32	11.9	8.89	32	8.3%	1.65 [−2.79, 6.09]
Guo, 2009 [25]	5.28	7.51	57	11.25	7.59	30	10.2%	−5.97 [−9.31, −2.63]
Kang, 2006 [30]	5.14	1.86	36	8.22	2.04	38	14.3%	−3.08 [−3.97, −2.19]
Lv, 2009 [39]	12.86	7.92	35	19.67	8.36	35	9.3%	−6.81 [−10.63, −2.99]
Wang and Yu, 2005 [38]	8.82	7.92	64	18.5	8.82	64	11.0%	−9.68 [−12.58, −6.78]
Zhang, 2004 [24]	7.12	7.45	40	14.56	7.4	40	10.4%	−7.44 [−10.69, −4.19]
Zhang et al., 2010 [12]	12.02	6.39	82	14.39	7.29	82	12.6%	−2.37 [−4.47, −0.27]
Zhang et al., 2012 [28]	11.26	2.56	36	17.84	3.86	34	13.5%	−6.58 [−8.12, −5.04]
Zheng et al., 2004 [40]	18.08	5.16	27	18.77	6.24	22	10.4%	−0.69 [−3.94, 2.56]
Total (95% CI)			409			377	100.0%	−4.65 [−6.57, −2.72]
Heterogeneity: Tau² = 6.54; Chi² = 49.62, df = 8 (P < 0.00001); 𝐼^2 = 84%
Test for overall effect: Z = 4.73 (P < 0.00001)